

Product Data Sheet

| Cas No.: | 1398695-47-0 | Cat. No: | PL02110 |
|---------------------|---|-------------------------------------|---------|
| Product Name: | GSK2646264 | | |
| Product synonym: | - | | |
| Chemical name: | GSK2646264 | | |
| MF: | C24H26N2O2 | FW: | 374.48 |
| Purity: | ≥98% | Batch No.: | - |
| Storage: | | , | |
| Structural formula: | NH N | | |
| λmax: | - | Formulation: | - |
| Solubility : | | | |
| SMILES: | N1CCC2=CC(C3=C(OCC4=NC=CC(C)=C4)C=CC=C3OC)=CC=C2CC1 | | |
| InChI Code: | | - | |
| InChl Key: | | | |
| | WARNING This product | is not for human or veterinary use. | |

Product Description

GSK2646264 (Compound 44) 是一种有效的、选择性的脾酪氨酸激酶 (SYK) 抑制剂,pIC₅₀ 值为 7.1。GSK2646264 对其他激酶也有抑制效果,对 LCK、LRRK2、GSK3β、JAK2、VEGFR2、Aurora B 和 Aurora A 的 pIC₅₀ 分别为 5.4、5.4、5.3、5、4.5、<4.6 和 <4.3。GSK2646264 可渗透到皮肤的表皮和真皮层。

| 生物活性 | GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC 50 of 7.1. GSK2646264 also inhibits other kinases with pIC 50 values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 against LCK, LRRK2, GSK3β, JAK2, VEGFR2, Aurora B and Aurora A, respectively. GSK2646264 is penetrable into the epidermis and dermis of the skin. | |
|---------------------|---|--|
| IC50 & Target[1][2] | SYK 7.1 (plC50) LCK 5.4 (plC50 | |
| 体外研究(In Vitro) | GSK2646264 (0.01-10 μ M; 1 h) significantly inhibits anti-IgE (but not C5a)-induced histamine release from skin mast cells in a concentration-dependent manner. The IC50 is 0.7 μ M and the IC90 is 6.8 μ M. GSK2646264 cream (0.5, 1, and 3% [wt/wt]; 1 cm; 4 and 24 h) inhibits anti-IgE-induced histamine release from mast cells in ex vivo human skin. has not independently confirmed the accuracy of these methods. They are for reference only. | |
| 包装储存 | 4°C, protect from light In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) | |

溶解度数据

In Vitro: DMSO : 50 mg/mL (133.52 mM; ultrasonic and warming and heat to 60° C)配制储备液